CA2677068A1 - Composes a base d'acides nucleiques pour l'inhibition de l'expression genique et utilisation desdits composes - Google Patents

Composes a base d'acides nucleiques pour l'inhibition de l'expression genique et utilisation desdits composes Download PDF

Info

Publication number
CA2677068A1
CA2677068A1 CA2677068A CA2677068A CA2677068A1 CA 2677068 A1 CA2677068 A1 CA 2677068A1 CA 2677068 A CA2677068 A CA 2677068A CA 2677068 A CA2677068 A CA 2677068A CA 2677068 A1 CA2677068 A1 CA 2677068A1
Authority
CA
Canada
Prior art keywords
rna
artificial sequence
seq
molecule
synthetic oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2677068A
Other languages
English (en)
Inventor
Steven C. Quay
James Mcswiggen
Narendra K. Vaish
Mohammad Ahmadian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
Marina Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marina Biotech Inc filed Critical Marina Biotech Inc
Priority to CA2677068A priority Critical patent/CA2677068A1/fr
Publication of CA2677068A1 publication Critical patent/CA2677068A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2677068A 2009-09-01 2009-09-01 Composes a base d'acides nucleiques pour l'inhibition de l'expression genique et utilisation desdits composes Abandoned CA2677068A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2677068A CA2677068A1 (fr) 2009-09-01 2009-09-01 Composes a base d'acides nucleiques pour l'inhibition de l'expression genique et utilisation desdits composes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2677068A CA2677068A1 (fr) 2009-09-01 2009-09-01 Composes a base d'acides nucleiques pour l'inhibition de l'expression genique et utilisation desdits composes

Publications (1)

Publication Number Publication Date
CA2677068A1 true CA2677068A1 (fr) 2011-03-01

Family

ID=43645990

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2677068A Abandoned CA2677068A1 (fr) 2009-09-01 2009-09-01 Composes a base d'acides nucleiques pour l'inhibition de l'expression genique et utilisation desdits composes

Country Status (1)

Country Link
CA (1) CA2677068A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3974530A4 (fr) * 2019-05-22 2023-07-12 Suzhou Ribo Life Science Co., Ltd. Acide nucléique, composition pharmaceutique, conjugué, procédé de préparation et utilisation
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
US12084661B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US11827695B2 (en) 2017-02-17 2023-11-28 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US12084661B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
EP3974530A4 (fr) * 2019-05-22 2023-07-12 Suzhou Ribo Life Science Co., Ltd. Acide nucléique, composition pharmaceutique, conjugué, procédé de préparation et utilisation

Similar Documents

Publication Publication Date Title
CA2677068A1 (fr) Composes a base d'acides nucleiques pour l'inhibition de l'expression genique et utilisation desdits composes
Khabar The AU-rich transcriptome: more than interferons and cytokines, and its role in disease
JP7551815B2 (ja) Ｔ細胞療法を向上させるための、哺乳動物ｔ細胞の活性化により誘導可能な合成プロモーター（ｓｙｎ＋ｐｒｏ）の作製
Nakasa et al. Expression of microRNA‐146 in rheumatoid arthritis synovial tissue
Lu et al. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-γ pathway, Th1 polarization, and the severity of delayed-type hypersensitivity
CN1286981C (zh) 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
EP2638159A2 (fr) Compositions, kits et méthodes de traitement des maladies cardio-vasculaires, immunologiques et inflammatoires
EP2077326A1 (fr) Nouvel acide nucléique
CN113249380B (zh) 靶向covid-19新冠病毒的反义寡核苷酸、natac嵌合分子及其应用
JP2013515498A (ja) ｃ−Ｍｅｔの発現を阻害するｓｉＲＮＡ及びこれを含む抗癌組成物
Gabner et al. Cytokine‐induced interleukin‐1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment
JP2022512922A (ja) キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法
Maruyama et al. Neat1 lncRNA organizes the inflammatory gene expressions in the dorsal root ganglion in neuropathic pain caused by nerve injury
CN101077883A (zh) 乙肝病毒基因的小干扰核糖核酸序列及制备方法
JP7213897B2 (ja) 核酸ユニットとその高分子核酸及びその応用
CN1800387A (zh) 抑制多效生长因子基因表达的小干扰rna及其应用
CN101974562B (zh) 染色质重塑蛋白4A在增强缺氧诱导因子1α稳定性及转录活性中的应用
CN110295168A (zh) lncRNA-AK143701抑制序列及其在制备抗气道炎症药物中的应用
CN103952406A (zh) 抑制人恶性脑胶质瘤增殖的靶向STAT3基因的siRNA及其表达载体和应用
CN103952410A (zh) 一种有效抑制大鼠FoxO3a基因表达的shRNA及其应用
WO2024172057A1 (fr) Construction de miarn artificiel
CN115786355B (zh) Tango6基因在促进细胞增殖中的应用以及方法
CN116036121B (zh) 人bub1基因在制备抗肿瘤药物中的用途
CN111378622B (zh) 核酸编码的car-t细胞及其制备方法和应用
CN1648250A (zh) 乙肝病毒基因的小干扰核糖核酸序列及制备方法

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20130904